NCT01754402 2024-02-20
Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma
Duke University
Phase 1/2 Unknown
Clinical Trials
41 trialsNCT04714827 2023-12-29
Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma
Shanxi Province Cancer Hospital
Phase 1/2 Unknown
NCT06126237 2023-11-13
A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma
Keymed Biosciences Co.Ltd
Phase 1/2 Unknown
NCT04942067 2023-10-25
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
Ascentage Pharma Group Inc.
Phase 1/2 Unknown
NCT04309981 2023-08-28
Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.
Institut d'Investigacions Biomèdiques August Pi i Sunyer
Phase 1/2 Unknown
NCT03090659 2023-06-12
LEGEND-2
Nanjing Legend Biotech Co.
Phase 1/2 Unknown
NCT05857982 2023-05-15
Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
Second Affiliated Hospital of Soochow University
Phase 1/2 Unknown
NCT05749133 2023-04-20
Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2 Unknown
NCT04272151 2023-04-18
Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT04674514 2023-03-07
APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma
Ascentage Pharma Group Inc.
Phase 1/2 Unknown
NCT05739188 2023-02-23
Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase 1/2 Unknown
NCT05672420 2023-01-05
Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2 Unknown
NCT04935580 2022-08-03
Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients
Shanghai Changzheng Hospital
Phase 1/2 Unknown
NCT05150522 2021-12-09
B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma
Shenzhen University General Hospital
Phase 1/2 Unknown
NCT05066646 2021-11-23
FUMANBA-1
Nanjing IASO Biotechnology Co., Ltd.
Phase 1/2 Unknown
NCT03670173 2021-05-19
Safety and Efficacy Assessments of Osalmid in Multiple Myeloma
Shanghai 10th People's Hospital
Phase 1/2 Unknown
NCT04891744 2021-05-18
Selinexor in Combination With Thalidomide and Dexamethasone in RRMM
Sichuan University
Phase 1/2 Unknown
NCT03795597 2021-04-26
BuMelCarAuto
Loyola University
Phase 1/2 Unknown
NCT04762745 2021-02-21
The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma
Sun Yat-sen University
Phase 1/2 Unknown
NCT03638206 2019-12-11
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Shenzhen BinDeBio Ltd.
Phase 1/2 Unknown
NCT03018405 2019-09-19
THINK
Celyad Oncology SA
Phase 1/2 Unknown
NCT02954445 2019-06-25
A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies
Southwest Hospital, China
Phase 1/2 Unknown
NCT03767751 2018-12-07
A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT03607643 2018-07-31
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
Leaf Vertical Inc.
Phase 1/2 Unknown
NCT03322735 2017-12-29
Study of BCMA CAR-T in Multiple Myeloma
Henan Cancer Hospital
Phase 1/2 Unknown
NCT03091933 2017-12-06
GLIDE
Ciusss de L'Est de l'Île de Montréal
Phase 1/2 Unknown
NCT02488382 2017-10-17
Lonquek for Autologous Stem Cell Mobilization
Sheba Medical Center
Phase 1/2 Unknown
NCT02519114 2017-02-10
Haploidentical Bone Marrow Stem Cell Transplantation in Patients With Multiple Myeloma
Maastricht University Medical Center
Phase 1/2 Unknown
NCT01522872 2016-06-02
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Threshold Pharmaceuticals
Phase 1/2 Unknown
NCT01886976 2016-01-28
CART-138
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT01812096 2015-08-18
MM
The First Affiliated Hospital of Soochow University
Phase 1/2 Unknown
NCT00800059 2015-07-27
TMI-ASCT
Ottawa Hospital Research Institute
Phase 1/2 Unknown
NCT02248402 2014-09-25
Vax-DC/MM
Chonnam National University Hospital
Phase 1/2 Unknown
NCT01435720 2014-09-11
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
Senesco Technologies, Inc.
Phase 1/2 Unknown
NCT02007811 2014-03-26
B-cell therapy
University of Erlangen-Nürnberg Medical School
Phase 1/2 Unknown
NCT00006466 2013-12-18
Beta Alethine in Treating Patients With Myeloma
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT01695590 2013-06-04
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
Prolexys Pharmaceuticals
Phase 1/2 Unknown
NCT01010243 2012-05-30
MM03
University of Regensburg
Phase 1/2 Unknown
NCT00431990 2011-08-12
A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma
Peter MacCallum Cancer Centre, Australia
Phase 1/2 Unknown
NCT01002703 2011-08-12
Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma
University of Leipzig
Phase 1/2 Unknown
NCT00048464 2006-11-07
T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant
Xcyte Therapies
Phase 1/2 Unknown